Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prostate Specific Antigen Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    188 result(s) found for: Prostate Specific Antigen Test. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005042-42 Sponsor Protocol Number: IASONFC303 Start Date*: 2021-06-27
    Sponsor Name:IASON GmbH
    Full Title: Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA ...
    Medical condition: Prostate cancer suspected clinically and on the basis of elevated serum Prostate Specific Antigen (PSA) levels and/or PSA density and with result of multiparametric Magnetic Resonance Imaging (mpMR...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10022891 - Investigations 10053838 Free prostate-specific antigen increased PT
    20.1 10022891 - Investigations 10050321 Prostate examination PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029096 Neoplasm prostate PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004385 Benign neoplasm of prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000566-38 Sponsor Protocol Number: GETUG-AFU_23_/_UC-0160/1202 Start Date*: 2014-07-23
    Sponsor Name:UNICANCER
    Full Title: A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse
    Medical condition: localized prostate cancer with high-risk features of relapse
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) DE (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021434-55 Sponsor Protocol Number: FE 200486 CS35A Start Date*: 2010-11-11
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002345-29 Sponsor Protocol Number: T83/2017 Start Date*: 2018-08-10
    Sponsor Name:Turku University Hospital
    Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004572-13 Sponsor Protocol Number: ARD-0301-010 Start Date*: 2006-11-06
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, lon...
    Medical condition: Locally advanced and/or metatstatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002571-11 Sponsor Protocol Number: ENHANCE Start Date*: 2022-11-25
    Sponsor Name:Institut Mutualiste Montsouris
    Full Title: EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate can...
    Medical condition: Intermediate risk localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004349-13 Sponsor Protocol Number: ARD-0301-012 Start Date*: 2007-11-12
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer – follow on study to Study ...
    Medical condition: Locally advanced and/or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004264-31 Sponsor Protocol Number: ARD-0301-004 Start Date*: 2007-02-23
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, open-label study investigating the efficacy and safety of a new GnRH antagonist, Teverelix, long-acting formulation in patients with advanced prostate cancer
    Medical condition: Locally advanced and/or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LV (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000101-69 Sponsor Protocol Number: EGD-EC-005 Start Date*: 2013-07-04
    Sponsor Name:Astellas Pharma Europe Ltd. (APEL)
    Full Title: An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Medical condition: Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021900-93 Sponsor Protocol Number: CLIN1001 PCM301 Start Date*: 2010-12-14
    Sponsor Name:STEBA BIOTECH SA
    Full Title: A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for low risk localised prostate cancer compared to Active Surveillance
    Medical condition: Low-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004094-25 Sponsor Protocol Number: EGD-EC-003 Start Date*: 2006-01-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who a...
    Medical condition: Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing ...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10060862 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) AT (Prematurely Ended) FI (Completed) SK (Completed) IE (Completed) HU (Completed) DE (Completed) ES (Completed) SE (Completed) GB (Completed) PT (Completed) BE (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021287-16 Sponsor Protocol Number: 9785-CL-0321 Start Date*: 2010-11-29
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer
    Medical condition: Hormone-naïve prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012786-58 Sponsor Protocol Number: 8-79-52014-168 Start Date*: 2009-12-07
    Sponsor Name:Ipsen Pharma SAS
    Full Title: PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (P...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) LV (Completed) FR (Completed) NL (Completed) LT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004355-30 Sponsor Protocol Number: 20070611 Start Date*: 2009-01-05
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer
    Medical condition: Previously Treated Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) FR (Completed) NL (Completed) FI (Completed) SE (Completed) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006913-34 Sponsor Protocol Number: FE200486 CS21A Start Date*: 2007-03-23
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation The...
    Medical condition: Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005665-12 Sponsor Protocol Number: MDV3100-14(C3431005) Start Date*: 2013-09-06
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Medical condition: Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IT (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) FI (Completed) NL (Completed) ES (Completed) GR (Completed) FR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003525-16 Sponsor Protocol Number: DOCRTPC Start Date*: 2007-05-02
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Neoadjuvant chemotherapy with weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advanced prostate cancer
    Medical condition: high risk locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005232-33 Sponsor Protocol Number: FE200486 CS30 Start Date*: 2009-04-15
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients o...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006595-38 Sponsor Protocol Number: SU/2006/2424 Start Date*: 2007-08-03
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl® SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection
    Medical condition: Enrolled patients will be those who have a diagnosis of prostate cancer and for whom medical castration by means of Luteinising Hormone Releasing Hormone analogue (LHRHa) injection is indicated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003740-39 Sponsor Protocol Number: URO-CHUAC-BPSat-001. Start Date*: 2016-04-12
    Sponsor Name:Jose Luis Ponce Díaz-Reixa
    Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy .
    Medical condition: Prostate biopsy anesthesia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10004825 Biopsy of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA